iBiomagazine

Open science rules that search to enhance science can successfully bridge the hole between researchers and environmental managers. Nonetheless, widespread adoption has but to achieve traction for the event and utility of bioassessment merchandise. On the core of this philosophy is the idea that analysis needs to be reproducible and clear, along with having long-term worth by means of efficient information preservation and sharing.

On this article, we evaluate core open science ideas which have not too long ago been adopted within the ecological sciences and emphasize how adoption can profit the sector of bioassessment for each prescriptive situation assessments and proactive functions that inform environmental administration. An instance from the state of California demonstrates efficient adoption of open science rules by means of information stewardship, reproducible analysis, and engagement of stakeholders with multimedia functions.

We additionally focus on technical, sociocultural, and institutional challenges for adopting open science, together with sensible approaches for overcoming these hurdles in bioassessment functions. Within the laboratory-based disciplines, choice of a principal investigator (PI) and analysis laboratory (lab) indelibly shapes doctoral college students’ experiences and academic outcomes.

Framed by the theoretical idea of person-environment match from inside a socialization mannequin, we use an inductive, qualitative method to discover how a pattern of 42 early-stage doctoral college students enrolled in organic sciences packages made choices about becoming with a PI and inside a lab. Outcomes illuminated a posh array of things that college students thought of in deciding on a PI, together with PI relationship, mentoring model, {and professional} stability.

Additional, with regard to college students’ lab choice, friends and analysis tasks performed an vital position. College students actively conceptualized trade-offs amongst varied dimensions of match. Our findings additionally revealed circumstances during which college students didn’t safe a place of their first (or second) alternative labs and needed to contemplate their potential match with suboptimal placements (when it comes to their preliminary assessments).

Thus, these college students weighted various factors of match towards the truth of needing to safe monetary assist to proceed of their doctoral packages. We conclude by presenting and framing implications for college kids, PIs, and doctoral packages, and advocate offering transparency and candor across the PI and lab choice processes.

γ-Nanofluid Thermal Transport between Parallel Plates Suspended by Micro-Cantilever Sensor by Incorporating the Efficient Prandtl Mannequin: Functions to Organic and Medical Sciences.

The movement of nanofluid between infinite parallel plates suspended by micro-cantilever sensors is critical. The evaluation of such flows is a wealthy analysis space as a result of number of functions it has in chemical, organic and medical sciences. Micro-cantilever sensors play a major position in precisely sensing totally different illnesses, and so they can be utilized to detect many hazardous and bio-warfare brokers.

Subsequently, movement water and ethylene glycol (EG) composed by γ-nanoparticles is used. Firstly, the governing nanofluid mannequin is reworked into two self-similar nanofluid fashions on the idea of their efficient fashions. Then, a numerical methodology is adopted for resolution functions, and each the nanofluid fashions are solved.

To reinforce the warmth switch traits of the fashions, the efficient Prandtl mannequin is ingrained within the vitality equation. The speed F'(η) decreases with respect to the suction of the fluid, as a result of extra fluid particles drags on the floor for suction, resulting in an abrupt decrement in F'(η). The speed F'(η) will increase for injection of the fluid from the higher finish, and subsequently the momentum boundary layer area is extended.

A excessive quantity fraction issue is accountable for the denser traits of the nanofluids, on account of which the fluids develop into extra viscous, and the speed F'(η) drops abruptly, with the magnetic parameters favoring velocity F'(η). A rise in temperature β ( η ) of Al₂O₃-H₂O and γAl₂O₃-C₂H₆O₂ nanofluids was reported at increased fraction components with permeable parameter results. Lastly, a comparative evaluation is offered by limiting the movement parameters, which exhibits the reliability of the examine.

A Core Curriculum within the Organic and Biomedical Sciences for Dentistry.

 

The biomedical sciences (BMS) are a central a part of the dental curriculum that underpins instructing and scientific observe in all areas of dentistry. Though some specialist teams have proposed curricula of their explicit subject areas, there may be at present no over-arching view of what needs to be included in a BMS curriculum for undergraduate dental programmes. To deal with this, the Affiliation for Dental Schooling in Europe (ADEE) convened a Particular Curiosity Group (SIG) with representatives from throughout Europe to develop a consensus BMS curriculum for dental programmes.

This paper summarises the end result of the deliberations of this SIG, and particulars a consensus view from the SIG of what a BMS curriculum ought to embody.Given the broad nature of BMS utilized to dentistry, this curriculum framework is advisory and seeks to supply programme planners with an indicative record of subjects which will be mapped to particular studying goals inside their very own curricula.

As dentistry turns into more and more specialised these will change, or some parts of the undergraduate curriculum might transfer to the postgraduate setting. So, this doc needs to be seen as a starting and it’ll want common evaluate as BMS curricula in dentistry evolve. The method of designing and implementing individualized health-promoting interventions, dietary or in any other case, is fraught with nice issue owing to the heterogeneity inherent in components that affect wholesome longevity.

NF-κB reporter (Luc) - HEK293 Cell line
60650	BPS Bioscience	2 vials	1365 EUR
Description: The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17.
NF-kB reporter (Luc) - HEK293 Cell line
GWB-PS76F8	GenWay Biotech	2X10(6)cells	Ask for price
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)
78172-1	BPS Bioscience	100 µl	835 EUR
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)
78172-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)
78204-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)
78204-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)
78205-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)
78205-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)
78206-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)
78206-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)
78215-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)
78215-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)
78614-1	BPS Bioscience	100 µl	860 EUR
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)
78614-2	BPS Bioscience	500 µl x 2	4320 EUR
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
NF- κB Reporter (Luc) - Raw 264.7 Cell line
79978	BPS Bioscience	2 vials	2045 EUR
Description: The NF-κB reporter (Luc)-Raw 264.7 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.
Oct4 CR4-pGreenFire Response Reporter (virus)
SR20070-VA-1	SBI	>2 x 10^6 IFUs	670 EUR
NF- κB Reporter (Luc) - THP-1 Cell Line
79645	BPS Bioscience	2 vials	1900 EUR
Description: The NF-κB reporter (Luc)-THP-1 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.
PAI-1 Reporter (Luc) - Mv1 Lu Cell Line
60544	BPS Bioscience	2 vials	3595 EUR
Description: PAI-1 Reporter (Luc)-Mv1 Lu cell line is designed for monitoring transforming growth factor β (TGF-β)-induced plasminogen activator inhibitor-1 (PAI-1) expression. Transforming growth factor-β (TGF-β) is a potent regulator of cellular differentiation, proliferation, migration, and protein expression._x000D__x000D_PAI-1 Reporter (Luc) -Mv1 Lu cell line contains a firefly luciferase gene under the control of PAI-1 responsive elements stably integrated into Mv1 Lu (NBL-7) cells, showing TGF-β pathway response. This cell line is validated for the TGF-β response to the induction of PAI-1 gene expression through luciferase activity. _x000D_
NF-κB reporter (Luc) - NIH/3T3 Cell line
79469	BPS Bioscience	2 vials	1900 EUR
Description: The NF-κB reporter (Luc)-NIH/3T3 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.
pGreenZeo lenti reporter
PVTY00164	Nova Lifetech	2ug	280 EUR
NF-κB Reporter (Luc) - CHO-K1 Cell Line
60622	BPS Bioscience	2 vials	1095 EUR
Description: An NF-κB luciferase reporter construct is stably integrated into the genome of CHO-K1 cells. The firefly luciferase gene is controlled by the NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase / CHO-K1 cell line is suitable for monitoring the activity of NF-κB transcription factor through luminescence readout.). This cell line responds to human cytokine IL-1β, responds moderately to human TNF, and does not respond to human IFN-λ (2 µg/ml). Reducing the amount of serum during incubation period may increase the sensitivity to cytokines. Since CHO-K1 cells do not express endogenous human proteins, this cell line provides an excellent platform to enable exogenous expression of a protein of interest to study its downstream effect on NF-κB signaling.
Rat NSE Differentiation Reporter (pGreenZeo, Virus)
SR10024VA-1	SBI	>2 x 10^6 IFUs	691 EUR
STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin)
79800-P	BPS Bioscience	2 vials	3730 EUR
Description: The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.
Human GFAP Differentiation Reporter (pRedZeo, Virus)
SR10051VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Foxp3 Reporter (Luc) - Jurkat Recombinant Cell Line
60628	BPS Bioscience	2 vials	7645 EUR
Description: Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter.
Mouse MBP Differentiation Reporter (pGreenZeo, Virus)
SR10026VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human LCK Differentiation Reporter (pGreenZeo, Virus)
SR10032VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human B29 Differentiation Reporter (pGreenZeo, Virus)
SR1004VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse B29 Differentiation Reporter (pGreenZeo, Virus)
SR1005VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse CD8 Differentiation Reporter (pGreenZeo, Virus)
SR1006VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human CD2 Differentiation Reporter (pGreenZeo, Virus)
SR1009VA-1	SBI	>2 x 10^6 IFUs	691 EUR
NF-κB Reporter (Luc) - A549 Stable Cell Line
60625	BPS Bioscience	2 vials	1915 EUR
Description: NF-κB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.
STAT5 Reporter (Luc)- U937 Cell Line (GM-CSF)
79941	BPS Bioscience	2 vials	1980 EUR
Description: The STAT5 Reporter (Luc)-U937 cell line is designed for monitoring STAT5 signal transduction pathway in the U937 cell line. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by GM-CSF, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.
Rev-A3-GFP/Luc HIV Reporter Cells
HRC-3	101Bio	1 vial of 5x10⁶ cells	1800 EUR
Mouse Actc Differentiation Reporter (pGreenZeo, Virus)
SR10010VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human GFAP Differentiation Reporter (pGreenZeo, Virus)
SR10015VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse GFAP Differentiation Reporter (pGreenZeo, Virus)
SR10016VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus)
SR10018VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse CD44 Differentiation Reporter (pGreenZeo, Virus)
SR10020VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human BM88 Differentiation Reporter (pGreenZeo, Virus)
SR10021VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Rat Nestin Differentiation Reporter (pGreenZeo, Virus)
SR10034VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse ALBP Differentiation Reporter (pGreenZeo, Virus)
SR10036VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human NGN3 Differentiation Reporter (pGreenZeo, Virus)
SR10037VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human PDX1 Differentiation Reporter (pGreenZeo, Virus)
SR10039VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus)
SR10040VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human MAP2 Differentiation Reporter (pGreenZeo, Virus)
SR10047VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human ACTC Differentiation Reporter (pGreenZeo, Virus)
SR10049VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human NKX2.5 Differentiation Reporter (pGreenZeo, virus)
SR10067VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse CD68 Differentiation Reporter (pGreenZeo, Virus)
SR1008VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Rev-CEM-GFP/Luc HIV Reporter Cells
HRC-5	101Bio	1 vial of 5x10⁶ cells	1500 EUR
Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus)
SR10012VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus)
SR10013VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse SM22a Differentiation Reporter (pGreenZeo, Virus)
SR10014VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human CD11b Differentiation Reporter (pGreenZeo, Virus)
SR10017VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus)
SR10023VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human Opsin Differentiation Reporter (pGreenZeo, Virus)
SR10027VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human FABP7 Differentiation Reporter (pGreenZeo, Virus)
SR10048VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human 5-HT1A (Luc) HEK293 Reporter Cell
CHEK-ATF131	ACROBIOSYSTEMS	2Vials	14209.6 EUR
Description: This gene encodes a G protein-coupled receptor for 5-hydroxytryptamine (serotonin), and belongs to the 5-hydroxytryptamine receptor subfamily. Serotonin has been implicated in a number of physiologic processes and pathologic conditions. Inactivation of this gene in mice results in behavior consistent with an increased anxiety and stress response. Mutation in the promoter of this gene has been associated with menstrual cycle-dependent periodic fevers.
Rev-A3R5-GFP/Luc HIV Reporter Cells
HRC-2	101Bio	1 vial of 5x10⁶ cells	1900 EUR
Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus)
SR1001VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus)
SR10022VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human Nestin Differentiation Reporter (pGreenZeo, Virus)
SR10035VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)
78028-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)
78028-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_
Human Insulin Differentiation Reporter (pGreenZeo, Virus)
SR10028VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)
78348-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)
78348-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).
Lentiviral Dual Reporter: CMV-GFP-T2A-Luciferase pre-packaged virus
BLIV101VA-1	SBI	>2 x10^6 IFUs	722 EUR
Lentiviral Dual Reporter: UBC-RFP-T2A-Luciferase pre-packaged virus
BLIV200VA-1	SBI	>2 x10^6 IFUs	722 EUR
Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus)
SR10050VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Lentiviral Triple Reporter: CMV-Luciferase-RFP-TK pre-packaged virus
BLIV102VA-1	SBI	>2 x10^6 IFUs	722 EUR
Lentiviral Triple Reporter: UBC-Luciferase-RFP-TK pre-packaged virus
BLIV202VA-1	SBI	>2 x10^6 IFUs	722 EUR
Lentiviral Triple Reporter: MSCV-Luciferase-RFP-TK pre-packaged virus
BLIV302VA-1	SBI	>2 x10^6 IFUs	722 EUR
Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus)
SR1003VA-1	SBI	>2 x 10^6 IFUs	691 EUR
NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line
60651	BPS Bioscience	2 vials	2340 EUR
Description: NF-κB luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by 4 copies of NF-kB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.
Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus)
SR10019VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human SPP-1 Differentiation Reporter (pGreenZeo, Virus)
SR1002VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human MLC-2v Differentiation Reporter (pGreenZeo, Virus)
SR10011VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro
SR10015VA-P	SBI	>2 x 10^6 IFUs	691 EUR
Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus)
SR1007VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus)
SR10038VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)
78218-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)
78218-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.
Rev-CEM-Luc HIV Reporter Cells
HRC-6	101Bio	1 vial of 5x10⁶ cells	1500 EUR
CD40/NF-κB Reporter (Luc) - HEK293 Stable Cell Line
60626	BPS Bioscience	2 vials	6825 EUR
Description: Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene. _x000D_
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)
78112-1	BPS Bioscience	100 µl	875 EUR
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)
78112-2	BPS Bioscience	500 µl x 2	4405 EUR
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)
79982-1	BPS Bioscience	100 µl	1075 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)
79982-2	BPS Bioscience	500 µl x 2	8110 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_
Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus)
SR10025VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus)
SR10041VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway)
60520	BPS Bioscience	2 vials	2175 EUR
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β -catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter.
GITR / NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line
60546	BPS Bioscience	2 vials	10175 EUR
Description: This cell line expresses a surface human GITR (glucocorticoid-induced TNFR family related gene; TNFRSF18; CD357) and an NF-κB luciferase reporter construct that are stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. The cells have been validated using purified human GITRL and anti-GITR neutralizing antibody.
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78142-1	BPS Bioscience	100 µl	860 EUR
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78142-2	BPS Bioscience	500 µl x 2	4320 EUR
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78144-1	BPS Bioscience	100 µl	835 EUR
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78144-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_
Sox2 SRR2-pGreenFire Response Reporter, pre-packaged virus
SR20071-VA-1	SBI	>2 x 10^6 IFUs	670 EUR
GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway)
79041	BPS Bioscience	2 vials	1810 EUR
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene.
Human E-Cadherin, CDH1 Differentiation Reporter (pGreenZeo, virus)
SR10070VA-1	SBI	>2 x 10^6 IFUs	691 EUR
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78143-1	BPS Bioscience	100 µl	835 EUR
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78143-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_
Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78618-1	BPS Bioscience	100 µl	795 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.621 (also known as the Mu Variant) was first identified in Columbia in early 2021. This variant has a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.621 Variant Spike (Genbank Accession #QHD43416.1 with B.1.621 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.621, Mu Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against the B.1.621 variant in a Biosafety Level 2 facility.
Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78618-2	BPS Bioscience	500 µl x 2	3995 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.621 (also known as the Mu Variant) was first identified in Columbia in early 2021. This variant has a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.621 Variant Spike (Genbank Accession #QHD43416.1 with B.1.621 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.621, Mu Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against the B.1.621 variant in a Biosafety Level 2 facility.
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78625-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78625-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78645-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5.The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2.12.1 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2.12.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78645-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5.The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2.12.1 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2.12.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
Human Alpha-Actin 2, ACTA2 Differentiation Reporter (pGreenZeo, virus)
SR10068VA-1	SBI	>2 x 10^6 IFUs	691 EUR
BLIV 2.0 Reporter: CMV-Luciferase-EF1a-copGFP Pre-packaged Virus
BLIV511VA-1	SBI	>2 x10^6 IFUs	722 EUR
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78651-1	BPS Bioscience	100 µl	875 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. Among them, BA.4 and BA.5 have identical mutations on their spike protein. The spike protein of BA.4 and BA.5 are referred as BA.4/5 in this datasheet.The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.4/5 variant in a Biosafety Level 2 facility.As shown in Figures 2 and 3, the Spike Omicron BA.4/5 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.4/5, Omicron Variant:Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78651-2	BPS Bioscience	500 µl x 2	4405 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. Among them, BA.4 and BA.5 have identical mutations on their spike protein. The spike protein of BA.4 and BA.5 are referred as BA.4/5 in this datasheet.The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.4/5 variant in a Biosafety Level 2 facility.As shown in Figures 2 and 3, the Spike Omicron BA.4/5 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.4/5, Omicron Variant:Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
CRE/CREB Reporter (Luc) - HEK293 Cell Line (cAMP/PKA Signaling Pathway)
60515	BPS Bioscience	2 vials	2070 EUR
Description: The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line is designed for monitoring the activity of the cAMP/ PKA signaling pathway. The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into HEK293 cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase.
CRE/CREB Reporter (Luc) - Jurkat Cell Line (cAMP/PKA Signaling Pathway)
79636	BPS Bioscience	2 vials	1810 EUR
Description: The CRE/CREB Reporter (Luc) - Jurkat Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into Jurkat cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase. This cell line is validated for response to stimulation by Forskolin.
Human MLC-2v Differentiation Reporter (pGreenZeo, Virus), EF1-Neo Marker
SR10011VA-N	SBI	>2 x 10^6 IFUs	691 EUR
SRE Luciferase Reporter Lentivirus
78627	BPS Bioscience	500 µl x 2	835 EUR
Description: The SRE (Serum Response Element) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the Serum Response Element located upstream of the minimal TATA promoter . After transduction, activation of the MAPK/ERK signaling pathway in the target cells can be monitored by measuring the luciferase activity.
Myc Luciferase Reporter Lentivirus
78628	BPS Bioscience	500 µl x 2	835 EUR
Description: The Myc Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the Myc response element located upstream of the minimal TATA promoter and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the Myc signaling pathway in the target cells can be monitored by measuring the luciferase activity.
p53 Luciferase Reporter Lentivirus
78666	BPS Bioscience	500 µl x 2	835 EUR
Description: The p53 Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by p53 response elements located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, p53-regulated gene expression in the target cells can be monitored by measuring the luciferase activity.
HRE Luciferase Reporter Lentivirus
78668	BPS Bioscience	500 µl x 2	835 EUR
Description: The Hypoxia Response Element (HRE) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of a hypoxia response elements (HRE) located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the induction of hypoxia in the target cells can be monitored by measuring the luciferase activity.
ARE Luciferase Reporter Lentivirus
79869	BPS Bioscience	500 µl x 2	875 EUR
Description: The Nrf2 antioxidant response pathway plays an important role in the cellular antioxidant defense. Nrf2, a basic leucine zipper transcription factor, induces the expression of antioxidant and phase II enzymes by binding to the ARE (antioxidant response element) region of the gene promoter. Under basal conditions, Nrf2 is retained in the cytosol by binding to the cytoskeletal protein Keap1. Upon exposure to oxidative stress or other ARE activators, Nrf2 is released from Keap1 and translocates to the nucleus, where it can bind to the ARE, leading to the expression of antioxidant and phase II enzymes that protect the cell from oxidative damage. The ARE Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by ARE located upstream of the minimal TATA promoter. After transduction, activation of the Nrf2 antioxidant response pathway in the target cells can be monitored by measuring the luciferase activity.
GR-GAL4 Reporter (Luc)-HEK293 Cell Line (Glucocorticoid Receptor Pathway)
60655	BPS Bioscience	2 vials	2275 EUR
Description: The Glucocorticoid Receptor Pathway GAL4 Reporter (Luc) - HEK293 Cell Line contains a_x000D_firefly luciferase gene under the control of glucocorticoid receptor ligand binding domain that is_x000D_fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR) stably integrated into_x000D_HEK293 cells. This fusion construct activates firefly luciferase expression under the control of a_x000D_multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of_x000D_glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual_x000D_transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell_x000D_line is validated for response to stimulation of dexamethasone and to the treatment with_x000D_mifepristone, an inhibitor of the glucocorticoid signaling pathway.
TEAD Luciferase Reporter Lentivirus
79833	BPS Bioscience	500 µl x 2	875 EUR
Description: The Hippo pathway regulates cell proliferation and cell death. It is activated by high cell density and cell stress to stop cell proliferation and induce apoptosis. The mammalian Hippo pathway comprises MST kinases and LATS kinases. When the Hippo pathway is activated, MST kinases phosphorylate LATS kinases, which phosphorylate transcriptional co-activators YAP and TAZ. Unphosphorylated YAP and TAZ remain in nucleus and interact with TEAD/TEF transcriptional factors to turn on cell cycle-promoting gene transcription. However, when phosphorylated, YAP and TAZ are recruited from the nucleus to the cytosol, so that the YAP and TAZ-dependent gene transcription is turned off. Dysfunction of the Hippo pathway is frequently detected in human cancer and its down-regulation correlates with the aggressive properties of cancer cells and poor prognosis. The TEAD Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the TEAD response elements located upstream of the minimal TATA promoter. After transduction, activation of the Hippo pathway in the target cells can be monitored by measuring the luciferase activity._x000D_
STAT3 Luciferase Reporter Lentivirus
79744	BPS Bioscience	500 µl x 2	860 EUR
Description: The STAT3 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of STAT3-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the STAT3 signaling pathway in the target cells can be monitored by measuring the luciferase activity._x000D_
STAT5 Luciferase Reporter Lentivirus
79745	BPS Bioscience	500 µl x 2	835 EUR
Description: The STAT5 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of STAT5-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the STAT5 signaling pathway in the target cells can be monitored by measuring the luciferase activity.
Spike (BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78623-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 BA.1 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. A sub-lineage of BA.1 with an R346K substitution in the spike protein is classified as B.1.1.529 BA.1.1.The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 BA.1.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.1.529 BA.1.1 variant in a Biosafety Level 2 facility.The Spike B.1.1.529 BA.1.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in B.1.1.529 BA.1.1 Omicron Variant R346K:A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
Spike (BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78623-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 BA.1 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. A sub-lineage of BA.1 with an R346K substitution in the spike protein is classified as B.1.1.529 BA.1.1.The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 BA.1.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.1.529 BA.1.1 variant in a Biosafety Level 2 facility.The Spike B.1.1.529 BA.1.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in B.1.1.529 BA.1.1 Omicron Variant R346K:A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
pGL3 3'UTR reporter WT 1.3 kb CD274 Hs 3'UTR Final Plasmid
PVT17094	Nova Lifetech	2ug	216 EUR
A549-Dual NFkb-SEAP-IRF-Luc Reporter Cells
S0016001	Addexbio	One Frozen vial	1400 EUR
A3galt2 3'UTR Luciferase Stable Cell Line
TU200008	ABM	1.0 ml	Ask for price
A3GALT2 3'UTR Luciferase Stable Cell Line
TU000008	ABM	1.0 ml	2799.6 EUR
A3galt2 3'UTR Luciferase Stable Cell Line
TU101054	ABM	1.0 ml	Ask for price
NF-κB Luciferase Reporter Lentivirus
79564	BPS Bioscience	500 µl x 2	875 EUR
Description: The NF-κB Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After transduction, activation of the NF-κB signaling pathway in the target cells can be monitored by measuring the luciferase activity.
Sox2 SRR2-pGreenFire Response Reporter (pre-packaged virus, EF1-Puro marker)
SR20071-VA-P	SBI	>2 x 10^6 IFUs	670 EUR
CRE/CREB Luciferase Reporter Lentivirus
79580	BPS Bioscience	500 µl x 2	835 EUR
Description: The main role of the cAMP response element, or CRE, is mediating the effects of Protein Kinase A (PKA) by way of transcription. Upon phosphorylation, CREB forms a functionally active dimer that binds the CRE element within the promoters of target genes and activates transcription. CRE is at the focus of many extracellular and intracellular signaling pathways, including cAMP, calcium, GPCR (G-protein coupled receptors) and neurotrophins. The cAMP/PKA signaling pathway is critical to numerous life processes in living organisms.The CRE/CREB Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by multimerized cAMP response element (CRE) located upstream of the minimal TATA promoter. After transduction, activation of the cAMP/PKA signaling pathway in the target cells can be monitored by measuring the luciferase activity.
pGreenFire 2.0 NFkB reporter virus (pGF2-NFκB-rFluc-T2A-GFP-mPGK-Puro)
TR412VA-P	SBI	>2 x 10^6 IFUs	702 EUR
pGreenFire 2.0 NFAT reporter virus (pGF2-NFAT-rFluc-T2A-GFP-mPGK-Puro)
TR451VA-P	SBI	>2 x 10^6 IFUs	702 EUR
NFAT Luciferase-RFP Reporter Lentivirus
78617-H	BPS Bioscience	500 µl x 2	835 EUR
Description: The NFAT Luciferase-RFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and RFP (Red Fluorescent Protein) cassette driven by the NFAT response element located upstream of the minimal TATA promoter and a hygromycin or puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or RFP expression. RFP fluoresces red-orange when excited; it has an excitation wavelength of 553 nm, and an emission wavelength of 574 nm.
NFAT Luciferase-RFP Reporter Lentivirus
78617-P	BPS Bioscience	500 µl x 2	835 EUR
Description: The NFAT Luciferase-RFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and RFP (Red Fluorescent Protein) cassette driven by the NFAT response element located upstream of the minimal TATA promoter and a hygromycin or puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or RFP expression. RFP fluoresces red-orange when excited; it has an excitation wavelength of 553 nm, and an emission wavelength of 574 nm.
pGreenFire 2.0 AP-1 reporter virus (pGF2-AP1-rFluc-T2A-GFP-mPGK-Puro)
TR452VA-P	SBI	>2 x 10^6 IFUs	702 EUR
NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line
TR860A-1	SBI	>2 x 10^6 cells	3142 EUR
NFAT eGFP Reporter Lentivirus
79922	BPS Bioscience	500 µl x 2	875 EUR
Description: The NFAT eGFP Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain an enhanced GFP gene driven by the NFAT response element located upstream of the minimal TATA promoter. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by examining eGFP expression._x000D_
pGreenFire 2.0 HIF-1 reporter virus (pGF2-HIF1-rFluc-T2A-GFP-mPGK-Puro)
TR426VA-P	SBI	>2 x 10^6 IFUs	702 EUR
BLIV 2.0 Reporter: MSCV-Luciferase-EF1a-copGFP-T2A-Puro Pre-packaged Virus
BLIV713VA-1	SBI	>2 x10^6 IFUs	722 EUR
STAT3 eGFP Reporter Lentivirus
78197	BPS Bioscience	500 µl x 2	795 EUR
Description: The STAT3 eGFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain an eGFP gene under the control of a STAT3-responsive element located upstream of the minimal TATA promoter . After transduction, activation of the STAT3 signaling pathway in the target cells can be monitored by examining eGFP expression.
pGreenFire 2.0 TCF/LEF reporter virus (pGF2-TCF/LEF-rFluc-T2A-GFP-mPGK-Puro)
TR413VA-P	SBI	>2 x 10^6 IFUs	702 EUR
IL-2 Promoter Luciferase Reporter Lentivirus
79825	BPS Bioscience	500 µl x 2	795 EUR
Description: The IL-2 Promoter Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the human IL-2 promoter. After transduction, activation of the IL-2 signaling pathway in the target cells can be monitored by measuring the luciferase activity._x000D_
IL-8 Promoter Luciferase Reporter Lentivirus
79827	BPS Bioscience	500 µl x 2	795 EUR
Description: The IL-8 Promoter Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the human IL-8 promoter. After transduction, activation of the IL-8 signaling pathway in the target cells can be monitored by measuring the luciferase activity._x000D_
Bald Lentiviral Pseudovirion (Luciferase Reporter)
79943	BPS Bioscience	500 µl x 2	875 EUR
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the firefly luciferase gene driven by a CMV promoter as the reporter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_
NFAT Luciferase Reporter Lentivirus-79579-G
79579-G	BPS Bioscience	500 µl x 2	835 EUR
Description: The NFAT Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (hygromycin, puromycin, or G418) for the selection of stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity.
NFAT Luciferase Reporter Lentivirus-79579-H
79579-H	BPS Bioscience	500 µl x 2	860 EUR
Description: The NFAT Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter and an antibiotic selection gene (hygromycin or puromycin) for the selection of stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity.
NFAT Luciferase Reporter Lentivirus-79579-P
79579-P	BPS Bioscience	500 µl x 2	860 EUR
Description: The NFAT Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter and an antibiotic selection gene (hygromycin or puromycin) for the selection of stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity.
NF-κB eGFP Reporter Lentivirus
79926	BPS Bioscience	500 µl x 2	820 EUR
Description: The NF-κB eGFP Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain an enhanced GFP gene driven by the NF-κB response element located upstream of the minimal TATA promoter. After transduction, activation of the NF-κB signaling pathway in the target cells can be monitored by examining eGFP expression.
TCF Reporter Plasmid (TOPflash, TK-luciferase reporter)
MBS641020-0005mg	MyBiosource	0.005mg	1270 EUR
TCF Reporter Plasmid (TOPflash, TK-luciferase reporter)
MBS641020-5x0005mg	MyBiosource	5x0.005mg	5570 EUR
A3GALT2 3'UTR GFP Stable Cell Line
TU050008	ABM	1.0 ml	2799.6 EUR
A3galt2 3'UTR GFP Stable Cell Line
TU250008	ABM	1.0 ml	Ask for price
A3galt2 3'UTR GFP Stable Cell Line
TU151054	ABM	1.0 ml	Ask for price
XRE Luciferase Reporter Lentivirus (AhR Signaling)
78672	BPS Bioscience	500 µl x 2	835 EUR
Description: The Xenobiotic response element (XRE) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by three copies of an XRE located upstream of the minimal TATA promoter (Figure 1), and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the activation of aryl hydrocarbon receptor (AhR) in the target cells can be monitored by measuring the luciferase activity.
CRE/CREB eGFP Reporter Lentivirus
78153	BPS Bioscience	500 µl x 2	795 EUR
Description: The CRE/CREB eGFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain an eGFP gene driven by a multimerized cAMP response element (CRE) located upstream of the minimal TATA promoter . After transduction, activation of the cAMP/PKA signaling pathway in the target cells can be monitored by examining eGFP expression.
SBE Luciferase Reporter Lentivirus (TGFβ/SMAD Pathway)
79806	BPS Bioscience	500 µl x 2	875 EUR
Description: The SBE Luciferase Reporter Lentivirus (TGFβ/SMAD signaling pathway) are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by multimerized SBE-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the TGFβ/SMAD signaling pathway can be monitored by measuring the luciferase activity._x000D_
NFAT Luciferase-eGFP Reporter Lentivirus-78656-G
78656-G	BPS Bioscience	500 µl x 2	835 EUR
Description: The NFAT Luciferase-eGFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and eGFP cassette driven by the NFAT response element located upstream of the minimal TATA promoter (Figure 1) and a puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or eGFP expression.
NFAT Luciferase-eGFP Reporter Lentivirus-78656-P
78656-P	BPS Bioscience	500 µl x 2	835 EUR
Description: The NFAT Luciferase-eGFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and eGFP cassette driven by the NFAT response element located upstream of the minimal TATA promoter (Figure 1) and a puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or eGFP expression.
Luciferase Reporter Assay Kit
55R-1540	Fitzgerald	200 assays	180 EUR
Description: Assay Kit for detection of Luciferase Reporter in the research laboratory
Luciferase Reporter Assay Kit
K2181-200	ApexBio	200 assays	130 EUR
Luciferase Reporter Assay Kit
K801-200	Biovision	each	235.2 EUR
Luciferase Reporter Assay Kit
GWB-AXR371	GenWay Biotech	200 assays	Ask for price
pGreenFire 2.0 Estrogen response element reporter virus (pGF2-ERE-rFluc-T2A-GFP-mPGK-Puro)
TR455VA-P	SBI	>2 x 10^6 IFUs	702 EUR
AP1 Luciferase Reporter Lentivirus (JNK Signaling Pathway)
79823	BPS Bioscience	500 µl x 2	795 EUR
Description: The stress-activated protein kinase/c-jun N-terminal kinase (SAPK/JNK) family of proteins includes mitogen-activated protein kinases (MAPKs) that are activated by stress, inflammatory cytokines, mitogens, oncogenes, and inducers of cell differentiation and morphogenesis. Upon activation of the SAPK/JNK pathway, MAP Kinase Kinases phosphorylate and activate JNKs. The activated JNKs translocate to the nucleus where they phosphorylate and activate transcription factors such as c-Jun. c-Jun then binds to the activator protein-1 (AP1) response element and induces AP1 transcription. The AP1 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by AP1 response element located upstream of the minimal TATA promoter. After transduction, activation of the JNK signaling pathway and AP1 mediated activity in the target cells can be monitored by measuring the luciferase activity.
Bald Lentiviral Pseudovirion (eGFP Reporter)
79987	BPS Bioscience	500 µl x 2	835 EUR
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the eGFP gene driven by a CMV promoter as the reporter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_
7TFP CDH1 reporter
PVT34088	Nova Lifetech	2ug	280 EUR
pLuc Reporter Vector
110000	CH3 BioSystems	each	135 EUR
Description: A lucife
2C::tdTomato Reporter
PVT10473	Nova Lifetech	2ug	182 EUR
GAS Luciferase Reporter Lentivirus (IFN-γ/JAK/STAT1 Pathway)
78653	BPS Bioscience	500 µl x 2	835 EUR
Description: The GAS Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by three copies of the interferon gamma (IFN-γ) activated sites (GAS) located upstream of the minimal TATA promoter and a puromycin selection gene for the selection of stable clones. After transduction, the GAS-regulated gene expression in the target cells can be monitored by measuring the luciferase activity.
Dual Luciferase Reporter Assay Kit
DL101-01	Vazyme	100 rxn	90.5 EUR
Luciferase Reporter Gene Assay Kit
Z5030001	Biochain	200 assays	329 EUR
Luciferase Reporter Gene Assay Kit
Z5030002	Biochain	500 assays	636 EUR
Luciferase Reporter Gene Assay Kit
Z5030003	Biochain	1,000 assays	1118 EUR
Dual Luciferase Reporter Assay Kit
DL101-01-100rxns	Vazyme	100 rxns	93.71 EUR
pMIR- Reporter Plasmid
PVT1324	Nova Lifetech	2ug	182 EUR
NFAT Reporter (Luciferase) - THP-1 Cell Line
78320	BPS Bioscience	2 vials	1810 EUR
Description: The NFAT reporter (Luciferase)-THP-1 cell line is designed for monitoring the NFAT (nuclear factor of activated T-cells) signaling pathway in THP-1 cells by measuring luciferase activity. It contains a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter. Upon activation by NFAT activators such as Ionomycin, endogenous NFAT transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.
ISRE Luciferase Reporter Lentivirus (JAK/STAT Signaling Pathway)
79824	BPS Bioscience	500 µl x 2	820 EUR
Description: The JAK/STAT pathway is activated by various cytokines and growth factors and plays a critical role in cell growth, hematopoiesis, and immune response. In mammals, there are four JAKs (JAK1, JAK2, JAK3 and TYK2) and seven STAT proteins. IFNα is a Type I interferon. Binding of IFNα to its receptor leads to the activation of JAK1 and TYK2, which in turn phosphorylate and activate STAT1 and STAT2. The phosphorylated STAT1 and 2 form a heterodimer and bind to IRF9/p48, forming a protein complex ISGF3. This complex translocates to the nucleus and binds to the ISRE (Interferon Stimulated Response Element) in the promoter region, thereby promoting transcription of interferon-inducible genes. The ISRE Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by multimerized ISRE response element located upstream of the minimal TATA promoter. After transduction, the activity of Type I interferon-induced JAK/STAT signaling pathway in the target cells can be monitored by measuring the luciferase activity.
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
79942-1	BPS Bioscience	100 µl	875 EUR
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
79942-2	BPS Bioscience	500 µl x 2	4405 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_
CRE/CRE Reporter Kit
GWB-PS935F	GenWay Biotech	500reactions	Ask for price
Bald VSV Delta G (Luciferase Reporter)
78636-1	BPS Bioscience	100 µl	395 EUR
Description: The bald VSV Delta G (Luciferase Reporter) was produced without envelope glycoproteins. It contains the firefly luciferase gene as the reporter. The bald VSV Delta G (Luciferase Reporter) can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.
Bald VSV Delta G (Luciferase Reporter)
78636-2	BPS Bioscience	500 µl x 2	1995 EUR
Description: The bald VSV Delta G (Luciferase Reporter) was produced without envelope glycoproteins. It contains the firefly luciferase gene as the reporter. The bald VSV Delta G (Luciferase Reporter) can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.
pLCN DSB Repair Reporter
PVT32743	Nova Lifetech	2ug	280 EUR
Dual Luciferase Reporter Gene Assay Kit
KTA8010-1000T	Abbkine	1000 T	819 EUR
Dual Luciferase Reporter Gene Assay Kit
KTA8010-100T	Abbkine	100 T	149 EUR
Dual Luciferase Reporter Gene Assay Kit
KTA8010-each	Abbkine	each	Ask for price
7TFP CDH1 mutant reporter
PVT34000	Nova Lifetech	2ug	280 EUR
HRE Luciferase Reporter-HeLa Cell Line
RC1018	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The HRE Luciferase Reporter cell line is a stably transfected HeLa cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the hypoxia response element (HRE). In response to hypoxia (low oxygen), HREs of target genes are recognized and regulated by the hypoxia-inducible factors (HIFs) which belong to the family of basic helix-loop-helix transcription factors and form heterodimeric complex comprising the alpha subunit (HIF-1 alpha, HIF-2 alpha and HIF-3 alpha) and beta subunit (Arnt1, Arnt2 and Arnt3), among which HIF-1 alpha and HIF-2 alpha are predominant isoforms. Activation of HIFs can also be mediated by chemical hydroxylase inhibitors as hypoxia mimetics including the iron chelator desferrioxamine and cobalt chloride.The HRE induction by cobalt chloride is shown in Figure 1.
p53 Luciferase Reporter-HeLa Cell Line
RC1026	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The p53 Luciferase Reporter cell line is a stably transfected HeLa cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the p53 response element. p53 is a tumor suppressor that plays a crucial role in apoptosis and anticancer mechanisms. p53 reporter system is designed to monitor the p53-mediated signaling pathways.The p53 induction by doxorubicin is shown in Figure 1.
MRE Luciferase Reporter HEK293 Cell Line
RC1037	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The MRE Luciferase Reporter cell line is a stably transfected HEK 293 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the metal response element (MRE). MRE is targeted by MRE-binding transcription factor-1 (MTF-1) which is a zinc finger transcription factor and plays a major role in induction of metallothionein gene expression in response to cellular stress caused by heavy metals such as zinc and cadmium. The MRE induction by ZnSO4 is shown in Figure 1.
Lenti ORF clone of A3galt2 (mGFP-tagged ORF) - Rat alpha 1,3-galactosyltransferase 2 (A3galt2), (10 ug)
RR214916L4	Origene Technologies GmbH	10 µg	Ask for price
RARbeta Reporter Cell Line
GWB-PS5D33	GenWay Biotech	~2x10(6)cells	Ask for price
Spike (SARS-CoV-1) Pseudotyped Lentivirus (eGFP Reporter)-100 µl
78633-1	BPS Bioscience	100 µl	835 EUR
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and these viral infections led to the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (SARS-CoV-1) pseudotyped lentivirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) pseudovirus has been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951).
Nrf2 Luciferase Reporter-MCF7 Cell Line
RC1017	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The Nrf2 Luciferase Reporter cell line is a stably transfected MCF7 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the antioxidant response element (ARE). ARE is known to regulate expression and induction of various detoxifying enzyme genes in response to antioxidants and xenobiotics, and is primarily regulated by the Keap1-Nrf2 pathway in which induction and nuclear translocation of Nrf2 mediated by antioxidants and xenobiotics results in the binding of Nrf2 to ARE leading to the expression of defensive genes. The Nrf2 induction by dimethyl fumarate (DMF) is shown in Figure 1.
ATF6 Luciferase Reporter-HeLa Cell Line
RC1038	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The ATF6 Luciferase Reporter cell line is a stably transfected HeLa cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the activating transcription factor 6 (ATF6)-response element. ATF6 is a member of the basic-leucine zipper transcription factor family, which is located in the endoplasmic reticulum (ER) membranes and plays a central role in transcriptional activation of ER molecules.  The ATF6 induction by Tunicamycin is shown in Figure 1.
RARalpha Reporter Cell Line
GWB-PSA34A	GenWay Biotech	~2x10(6)cells	Ask for price
RARgamma Reporter Cell Line
GWB-PSB42E	GenWay Biotech	~2x10(6)cells	Ask for price
WNT TCF/LEF reporter kit
GWB-PS656B	GenWay Biotech	500rxns.	Ask for price
STAT1 Luciferase Reporter-HeLa Cell Line
RC1012	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	4536 EUR
Description: The STAT1 Luciferase Reporter cell line is a stably transfected HeLa cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the interferon (IFN) gamma activation sequence-based STAT1 response element, so that the cell line is designed to measure the transcriptional activity of STAT1. As a transcription factor, Signal Transducer and Activator of Transcription 1 (STAT1) is activated through phosphorylation at tyrosine 701 in response to various cytokines and growth factors such as IFN-alpha, IFN-gamma, IL-6, EGF and PDGF. The phosphorylated STAT1 forms homodimers or heterodimers with STAT3, and the dimers translocate to nucleus in which DNA binding/promoter induction occurs. The STAT1 induction by IFN-gamma is shown in Figure 1.
SRE Luciferase Reporter-HEK293 Cell Line
RC1032	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	2772 EUR
Description: The SRE Luciferase Reporter cell line is a stably transfected HEK 293 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the serum response element (SRE). The SRE reporter cell line is designed to monitor MAPK/ERK activity and can be used for studying GPCR-linked MAPK/ERK signaling pathways as well as screening of agonists, antagonists or signaling inhibitors related with the MAPK/ERK signaling pathways. Functional activity of the cell line has been validated by serum stimulation assay (Figure 1).
CRE Luciferase Reporter-HEK293 Cell Line
RC1034	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	2772 EUR
Description: The CRE Luciferase Reporter cell line is a stably transfected HEK 293 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the cAMP response element (CRE). The CRE   cell line is designed to monitor the cAMP/PKA signaling pathways and can be used for studying GPCR-linked cAMP/PKA signaling pathways as well as screening of agonists, antagonists or signaling inhibitors related with the cAMP/PKA signaling pathways. Functional activity of the cell line has been validated by serum stimulation assay (Figure 1).
SBE Luciferase Reporter-HEK293 Cell Line
RC1036	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The SBE Luciferase Reporter cell line is a stably transfected HEK 293 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the smad binding element (SBE). SMADs are intracellular signaling mediators that transduce extracellular signals from transforming growth factor beta (TGF-beta) ligands to the nucleus where they activate downstream gene transcription. The TGF-beta signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The SBE induction by TGF-beta is shown in Figure 1.
TCF/LEF Luciferase Reporter Lentivirus (Wnt/β-catenin Signaling Pathway)
79787	BPS Bioscience	500 µl x 2	875 EUR
Description: The TCF/LEF Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of TCF/LEF-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the Wnt/β-catenin signaling pathway in the target cells can be monitored by measuring the luciferase activity.
NFAT Luciferase Reporter-HEK293 Cell Line
RC1010	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The NFAT Luciferase Reporter cell line is a stably transfected HEK 293 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the Nuclear Factor of Activated T-cells (NFAT) response element, so that the cell line is designed to measure the transcriptional activity of NFAT. NFAT is a transcription factor originally found in activated T lymphocytes, and is now known to regulate not only T cell activation and differentiation but also the function of other immune cells including dendritic cells, B cells and megakaryocytes. The NFAT induction by calcium ionophore A23187 is shown in Figure 1.
NFAT Luciferase Reporter-RAW264.7 Cell Line
RC1011	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The NFAT Luciferase Reporter cell line is a stably transfected RAW264.7 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the Nuclear Factor of Activated T-cells (NFAT) response element, so that the cell line is designed to measure the transcriptional activity of NFAT. NFAT is a transcription factor originally found in activated T lymphocytes, and is now known to regulate not only T cell activation and differentiation but also the function of other immune cells including dendritic cells, B cells and megakaryocytes. The NFAT induction by calcium ionophore A23187 is shown in Figure 1.
iNOS Luciferase Reporter-RAW264.7 Cell Line
RC1015	BosterBio	1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.	1864.8 EUR
Description: The iNOS Luciferase Reporter cell line is a stably transfected RAW264.7 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the iNOS promoter. Inducible nitric oxide synthase (iNOS) is an inducible enzyme that catalyzes the production of nitric oxide (NO) from L-arginine. NO is one of the smallest signaling molecules that can diffuse into the cell and is involved in various physiological functions, pathogenesis of septic shock, many diseases associated with autoimmunity, and  tumorigenesis. iNOS gene is generally known to be induced by various proinflammatory cytokines and pathogen-associated molecular patterns such as Toll-like receptor (TLR) ligands. The iNOS induction by lipopolysaccharide (LPS), the TLR4 ligand, is shown in Figure 1.

×

This paper proposes that cautious consideration to a few rules ━ life course perspective, U-shaped considering, and complete organism considering ━ creates an attitudinal framework that can be utilized to reframe organic heterogeneity into the clinically related query: Who will profit? The seek for instruments to deal with the complexity of this heterogeneity has been dominated by technological advances, together with state-of-the-art “-omics” approaches and machine-based dealing with of “large information.” Right here, it’s proposed that language precision and nuanced class utilization may present crucial instruments for dealing with heterogeneity, thereby enabling interventionalists to design and implement methods to advertise wholesome longevity with better precision.

Recombinant Humanp21 Recombinant Protein

92-035

TWEAK, recombinant / TNFSF12, recombinant (Human)

054-85

TAGLN Recombinant Protein (Rat) (Recombinant- Tag)

RP232205

TAGLN2 Recombinant Protein (Rat) (Recombinant Tag)

RP232208

TAGLN3 Recombinant Protein (Rat) (Recombinant Tag)

RP232211

×